全文获取类型
收费全文 | 130041篇 |
免费 | 11702篇 |
国内免费 | 5686篇 |
专业分类
耳鼻咽喉 | 531篇 |
儿科学 | 3254篇 |
妇产科学 | 1283篇 |
基础医学 | 24518篇 |
口腔科学 | 1452篇 |
临床医学 | 10388篇 |
内科学 | 32194篇 |
皮肤病学 | 1822篇 |
神经病学 | 4877篇 |
特种医学 | 2023篇 |
外国民族医学 | 14篇 |
外科学 | 7461篇 |
综合类 | 17860篇 |
现状与发展 | 31篇 |
预防医学 | 13632篇 |
眼科学 | 1322篇 |
药学 | 13214篇 |
31篇 | |
中国医学 | 5176篇 |
肿瘤学 | 6346篇 |
出版年
2024年 | 205篇 |
2023年 | 1552篇 |
2022年 | 3905篇 |
2021年 | 4778篇 |
2020年 | 4274篇 |
2019年 | 4473篇 |
2018年 | 4387篇 |
2017年 | 4409篇 |
2016年 | 4939篇 |
2015年 | 5400篇 |
2014年 | 8157篇 |
2013年 | 8713篇 |
2012年 | 8112篇 |
2011年 | 8925篇 |
2010年 | 7288篇 |
2009年 | 6692篇 |
2008年 | 6620篇 |
2007年 | 6569篇 |
2006年 | 6032篇 |
2005年 | 5233篇 |
2004年 | 4505篇 |
2003年 | 3973篇 |
2002年 | 3210篇 |
2001年 | 3002篇 |
2000年 | 2375篇 |
1999年 | 2090篇 |
1998年 | 1882篇 |
1997年 | 1676篇 |
1996年 | 1419篇 |
1995年 | 1422篇 |
1994年 | 1275篇 |
1993年 | 1037篇 |
1992年 | 886篇 |
1991年 | 710篇 |
1990年 | 636篇 |
1989年 | 570篇 |
1988年 | 523篇 |
1987年 | 409篇 |
1986年 | 345篇 |
1985年 | 772篇 |
1984年 | 676篇 |
1983年 | 524篇 |
1982年 | 521篇 |
1981年 | 437篇 |
1980年 | 388篇 |
1979年 | 337篇 |
1978年 | 282篇 |
1977年 | 213篇 |
1976年 | 216篇 |
1975年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
Hepatitis C is a major public health problem worldwide. This disease is caused by the hepatitis C virus, which is characterised by its genetic diversity. The infection is usually asymptomatic. However, between 60% and 80% of HCV-infected individuals will progress to chronic hepatitis, 20% to liver cirrhosis in the medium-to long-term and, each year, between 1% and 4% of these patients with cirrhosis will develop hepatocellular carcinoma (HCC). A Spanish consensus document has recently been drafted to diagnose hepatitis C in a single step, consisting of active investigation (antibodies and viremia) in a single sample, which according to the experts, would reduce the time to access treatment and avoid tracking losses. To definitively change the hepatitis C treatment paradigm, direct-acting antiviral drugs (DAAs) have been approved, whose development has been based on achieving cure rates close to 100% regardless of the genotype of the virus, ie, pangenotypes, with good tolerance and bioavailability. These drugs have constituted a real therapeutic revolution. Supplement information: This article is part of a supplement entitled «SEIMC External Quality Control Programme. Year 2016», which is sponsored by Roche, Vircell Microbiologists, Abbott Molecular and Francisco Soria Melguizo, S.A.© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosasy Microbiología Clínica. All rights reserved. 相似文献
45.
《Molecular therapy》2020,28(6):1432-1441
- Download : Download high-res image (155KB)
- Download : Download full-size image
46.
47.
48.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
49.
50.
目的:分析延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响。方法:研究选取2017年1月~2017年12月某院肝二病区收治的112例乙型肝炎患者和2018年1月~2018年12月收治的98例乙型肝炎病毒患者作为研究对象,所有患者均进行抗病毒治疗,回顾性分析患者的病历资料。将2017年收治的112例患者作为常规组实施常规护理,将2018年收治的98例患者的作为研究组实施延续性护理,比较两组的护理效果。结果:研究组的治疗依从率为93.88%(92例),远高于常规组的77.68%(87例),两组数据比较存在统计学意义(P<0.05)。结论:延续性护理措施可以有效提高慢性乙型肝炎抗病毒治疗的依从性,可以在临床中推广使用。 相似文献